Block et al. showed in a placebo-controlled clinical trial in non-dialysis CKD patients that ferric citrate significantly reduces intact FGF23 and serum phosphate levels among patients with elevated baseline phosphate (≥4.5 mg/dL). Here, FGF23 is linked to chronic kidney disease.